Clarassance, Inc.
Records under this name other than the patents Clarassance, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Showing 1 to 6 of 6 · Back to Clarassance, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,957,018 | Recombinant Human CC10 Protein for Treatment of Influenza Formerly held In force · High confidence | In force | High confidence | |
| US 9,394,349 | Modification and Compositions of Human Secretoglobin Proteins Formerly held In force · High confidence | In force | High confidence | |
| US 7,122,344 | Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions Formerly held Term ended Term ended Sep 22, 2017 · USPTO record | Term ended | Term ended Sep 22, 2017 | USPTO record |
| US 6,255,281 | Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions Formerly held Term ended Term ended May 28, 2017 · USPTO record | Term ended | Term ended May 28, 2017 | USPTO record |
| US 7,846,899 | Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease Formerly held Term ended Term ended May 28, 2017 · USPTO record | Term ended | Term ended May 28, 2017 | USPTO record |
| US 8,470,767 | Methods and compositions for the reduction of neutrophil influx and the treatment of bronchopulmonary displasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease Term ended Term ended May 28, 2017 · USPTO record | Term ended | Term ended May 28, 2017 | USPTO record |